Zura Bio Ltd (ZURA) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical...

Form 8-K - Current report

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune...

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune...

Form 3 - Initial statement of beneficial ownership of securities

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on...

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness